Arbutus Other Liab from 2010 to 2025

ABUS Stock  USD 3.30  0.03  0.90%   
Arbutus Biopharma Other Liabilities yearly trend continues to be comparatively stable with very little volatility. Other Liabilities will likely drop to about 18.6 M in 2025. From the period from 2010 to 2025, Arbutus Biopharma Other Liabilities quarterly data regression had r-value of  0.06 and coefficient of variation of  133.80. View All Fundamentals
 
Other Liabilities  
First Reported
2000-03-31
Previous Quarter
23.9 M
Current Value
16 M
Quarterly Volatility
9.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 701.5 K or Selling General Administrative of 27.1 M, as well as many indicators such as Price To Sales Ratio of 13.01, Dividend Yield of 0.0529 or PTB Ratio of 8.02. Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.
  
Check out the analysis of Arbutus Biopharma Correlation against competitors.

Latest Arbutus Biopharma's Other Liab Growth Pattern

Below is the plot of the Other Liab of Arbutus Biopharma Corp over the last few years. It is Arbutus Biopharma's Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arbutus Biopharma's overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Very volatile
   Other Liab   
       Timeline  

Arbutus Other Liab Regression Statistics

Arithmetic Mean26,998,218
Geometric Mean13,037,359
Coefficient Of Variation133.80
Mean Deviation18,988,547
Median21,945,000
Standard Deviation36,122,566
Sample Variance1304.8T
Range153.5M
R-Value0.06
Mean Square Error1392.8T
R-Squared0
Significance0.82
Slope465,088
Total Sum of Squares19572.6T

Arbutus Other Liab History

202518.6 M
202427.5 M
202223.9 M
202121.6 M
202023 M
201921.9 M
201816.4 M

About Arbutus Biopharma Financial Statements

Arbutus Biopharma shareholders use historical fundamental indicators, such as Other Liab, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Arbutus Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Other Liabilities27.5 M18.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.